-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, under the multiple resonances of policies, talents, market access, and financing channels, the local innovative drug industry has ushered in a big explosion
.
In this context, news of innovative drug companies' listings and financing continues, and the ability to "attract gold" continues to increase
.
For example, on December 15, 2021, BeiGene was officially listed on the Science and Technology Innovation Board, becoming the first biotech company to be listed on the US, Hong Kong and A shares
.
This time, BeiGene is priced at 192.
6 yuan per share, and the number of publicly issued shares is about 115 million shares.
It is expected to raise 22.
2 billion yuan
.
The funds raised will be used for drug clinical trial R&D projects, R&D center construction projects, production base R&D and industrialization projects, marketing network construction projects, and supplementary working capital
.
On December 10, Dizhe Pharmaceutical, an unprofitable biopharmaceutical company, also successfully landed on the Sci-tech Innovation Board.
The company is a pharmaceutical company that adopts the fifth set of listing standards and uses its own translational scientific research capabilities and technology platform to explore the clinical characteristics of diseases.
The relationship with possible abnormal driver genes and protein structure, with the goal of launching First-in-class and breakthrough potential therapeutic methods, and striving to fill the unmet clinical needs
.
In addition to BeiGene and Dizhe Pharmaceuticals, a number of innovative drug companies such as Rongchang Biologics and Maiwei Biologics, China's new antibody drug giants, have recently been approved for listing on the Science and Technology Innovation Board
.
According to incomplete statistics, 34 biomedical companies will be listed on the Sci-tech Innovation Board in 2021, which is higher than 28 in 2020 and 14 in 2019
.
The industry pointed out that, in the context of the vigorous development of local innovative drugs, domestic pharmaceutical companies have become investors' “sweet and delicious”
.
"In the first half of the year alone, the number of IPO pharmaceutical companies on the Science and Technology Innovation Board has reached 23, with a total financing amount of over 18 billion yuan
.
" Among them, many pharmaceutical companies including Aotai Biotechnology, Zhijiang Biotechnology, Baike Biotechnology and other pharmaceutical companies have raised funds.
More than 1 billion yuan
.
In the second half of the year, news about the financing of innovative drug companies also continued.
For example, recently, RNA innovative drug developer Xingrui Pharmaceutical announced that it has completed an angel round of financing of nearly 10 million US dollars, which was jointly led by Hillhouse Ventures and Sherpa Investment.
.
The funds raised this time will be used for the establishment of an mRNA tissue-specific targeting technology platform and pipeline advancement; In early December, Boaoxin Biotechnology, an innovative drug development biotechnology company in the global clinical stage, announced that it has completed a total of 200 million yuan in financing (Including the arrival of the PreB round of funding) to accelerate the company's investment in the clinical and preclinical innovation pipelines for targeted tumors and immune diseases; at the end of November, Lingtai Bio, which focuses on the development of new drugs for tumors and autoimmune diseases, announced the completion Pre-A round of financing, this round of financing was led by Yuansheng Venture Capital, and the old shareholder Zhang Ke led the continued additional investment
.
According to statistics from McKinsey, China accounted for 14% of global pipeline drugs for innovative drugs in 2021
.
Hillhouse recently stated that it continues to be optimistic about the development of China's innovative drugs in the next 10-15 years, and will continue to focus on China's high-quality biotech
.
In addition, many securities businesses continue to be optimistic about the innovative drug sector.
For example, Changsheng Fund recently believed that the innovative drug industry chain is undoubtedly the main line of investment in the pharmaceutical sector, of which CXO and bulk drugs are worthy of long-term optimism
.
The trend of industrial transfer is very obvious.
In the future, the entire industry will accelerate and the fundamentals are very strong; CICC believes that the development of China's pharmaceutical industry has entered the product-side logic, the internationalization of China's innovative products has begun, and the Hong Kong stock market has relatively small innovative drugs.
In the next few years, He Apparatus Company will show strong explosiveness in the process of internationalization
.
.
In this context, news of innovative drug companies' listings and financing continues, and the ability to "attract gold" continues to increase
.
For example, on December 15, 2021, BeiGene was officially listed on the Science and Technology Innovation Board, becoming the first biotech company to be listed on the US, Hong Kong and A shares
.
This time, BeiGene is priced at 192.
6 yuan per share, and the number of publicly issued shares is about 115 million shares.
It is expected to raise 22.
2 billion yuan
.
The funds raised will be used for drug clinical trial R&D projects, R&D center construction projects, production base R&D and industrialization projects, marketing network construction projects, and supplementary working capital
.
On December 10, Dizhe Pharmaceutical, an unprofitable biopharmaceutical company, also successfully landed on the Sci-tech Innovation Board.
The company is a pharmaceutical company that adopts the fifth set of listing standards and uses its own translational scientific research capabilities and technology platform to explore the clinical characteristics of diseases.
The relationship with possible abnormal driver genes and protein structure, with the goal of launching First-in-class and breakthrough potential therapeutic methods, and striving to fill the unmet clinical needs
.
In addition to BeiGene and Dizhe Pharmaceuticals, a number of innovative drug companies such as Rongchang Biologics and Maiwei Biologics, China's new antibody drug giants, have recently been approved for listing on the Science and Technology Innovation Board
.
According to incomplete statistics, 34 biomedical companies will be listed on the Sci-tech Innovation Board in 2021, which is higher than 28 in 2020 and 14 in 2019
.
The industry pointed out that, in the context of the vigorous development of local innovative drugs, domestic pharmaceutical companies have become investors' “sweet and delicious”
.
"In the first half of the year alone, the number of IPO pharmaceutical companies on the Science and Technology Innovation Board has reached 23, with a total financing amount of over 18 billion yuan
.
" Among them, many pharmaceutical companies including Aotai Biotechnology, Zhijiang Biotechnology, Baike Biotechnology and other pharmaceutical companies have raised funds.
More than 1 billion yuan
.
In the second half of the year, news about the financing of innovative drug companies also continued.
For example, recently, RNA innovative drug developer Xingrui Pharmaceutical announced that it has completed an angel round of financing of nearly 10 million US dollars, which was jointly led by Hillhouse Ventures and Sherpa Investment.
.
The funds raised this time will be used for the establishment of an mRNA tissue-specific targeting technology platform and pipeline advancement; In early December, Boaoxin Biotechnology, an innovative drug development biotechnology company in the global clinical stage, announced that it has completed a total of 200 million yuan in financing (Including the arrival of the PreB round of funding) to accelerate the company's investment in the clinical and preclinical innovation pipelines for targeted tumors and immune diseases; at the end of November, Lingtai Bio, which focuses on the development of new drugs for tumors and autoimmune diseases, announced the completion Pre-A round of financing, this round of financing was led by Yuansheng Venture Capital, and the old shareholder Zhang Ke led the continued additional investment
.
According to statistics from McKinsey, China accounted for 14% of global pipeline drugs for innovative drugs in 2021
.
Hillhouse recently stated that it continues to be optimistic about the development of China's innovative drugs in the next 10-15 years, and will continue to focus on China's high-quality biotech
.
In addition, many securities businesses continue to be optimistic about the innovative drug sector.
For example, Changsheng Fund recently believed that the innovative drug industry chain is undoubtedly the main line of investment in the pharmaceutical sector, of which CXO and bulk drugs are worthy of long-term optimism
.
The trend of industrial transfer is very obvious.
In the future, the entire industry will accelerate and the fundamentals are very strong; CICC believes that the development of China's pharmaceutical industry has entered the product-side logic, the internationalization of China's innovative products has begun, and the Hong Kong stock market has relatively small innovative drugs.
In the next few years, He Apparatus Company will show strong explosiveness in the process of internationalization
.
